Abivax stock price target raised to $95 from $33 at JMP on strong trial data

Published 23/07/2025, 09:54
Abivax stock price target raised to $95 from $33 at JMP on strong trial data

Investing.com - JMP Securities raised its price target on Abivax (NASDAQ:ABVX) to $95.00 from $33.00 on Wednesday, while maintaining a Market Outperform rating following positive Phase 3 trial results for the company’s ulcerative colitis treatment. The stock, which has surged over 64% in the past six months according to InvestingPro data, currently trades around $10 per share.

The significant price target increase follows Abivax’s announcement of positive results from two Phase 3 induction trials for obefazimod in moderate-to-severe ulcerative colitis.

JMP highlighted the "highly compelling" nature of the results, noting a pooled, placebo-adjusted clinical remission rate of 16.4% with statistical significance (p

The research firm increased its probability of approval and sales projections for obefazimod, which directly contributed to the nearly threefold increase in price target.

JMP believes these stellar Phase 3 results support the potential for "broad and early use in clinical practice" for obefazimod, according to its analysis of the trial data.

In other recent news, Abivax SA (EPA:ABVX) announced that its oral ulcerative colitis treatment, obefazimod, met primary endpoints in two Phase 3 induction trials. The trials demonstrated statistically significant clinical remission rates compared to placebo, with a 16.4% placebo-adjusted clinical remission rate after eight weeks. Citizens JMP reiterated a Market Outperform rating on Abivax, maintaining a $33.00 price target, citing confidence in the drug’s promising Phase 2b performance. Piper Sandler also reiterated an Overweight rating with a $42.00 price target, emphasizing obefazimod’s differentiated profile based on Phase 2 data. Additionally, Abivax successfully completed enrollment for its Phase 3 trials, marking significant progress in the drug’s development. The company plans to report top-line results from these trials in the third quarter of 2025. This development has reinforced the positive outlook from analysts, who are closely monitoring the upcoming clinical trial results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.